A Study of S1/Temozolomide (STEM) Regimen in Patients with Metastatic Neuroendocrine Tumors

#1611

Introduction: Both single agent Capecitabine alone or Capecitabine in combination with Temozolomide have activity against neuroendocrine tumors (NETs), however, the role of S-1 in NETs is still unknown.

Aim(s): We performed a study to evaluate the safety and efficacy of S-1 plus temozolomide (STEM) regimen in patients with locally advanced or metastatic NETs.

Materials and methods: A retrospective review was conducted of 14 patients with locally advanced or metastatic NETs who treated with STEM regimen. 12(85.71%) patients had failed to one or more line treatment of somatostatin analogues, Sunitinib, Everolimus, Anlotinib or other chemotherapy regimen. Patients received S-1 at 40mg/m2 orally twice daily on days 1–14 and temozolomide 200 mg orally once daily on days 10–14 of a 21-day cycle. Patients were followed for evidence of object response, toxicity , and progression-free survival (PFS).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Yihebali C, Jiuda Z, Yufeng W, Ba B, Liming J,

Keywords: Neuroendocrine tumors, Chemotherapy, S1,Temozolomide,